Molecular Partners (MOLN) Projected to Post Quarterly Earnings on Thursday

Molecular Partners (NASDAQ:MOLN) will likely be announcing its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 3:00 AM ET.

Molecular Partners (NASDAQ:MOLN) last posted its earnings results on Monday, August 25th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.14). On average, analysts expect Molecular Partners to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Molecular Partners Stock Performance

NASDAQ MOLN opened at $3.66 on Wednesday. The firm’s fifty day moving average price is $3.73 and its two-hundred day moving average price is $3.77. The stock has a market cap of $147.59 million, a PE ratio of -1.76 and a beta of 1.09. Molecular Partners has a fifty-two week low of $3.36 and a fifty-two week high of $6.63.

Wall Street Analyst Weigh In

A number of analysts have weighed in on MOLN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a research note on Tuesday, October 14th. JPMorgan Chase & Co. decreased their price target on shares of Molecular Partners from $4.50 to $4.00 and set a “neutral” rating for the company in a research report on Wednesday, September 3rd. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.00.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.